Our Blog

 

Potential Cognitive Benefits of Intensive Blood Pressure Lowering

By Heather Nelson Cortes PhD and Kevin C Maki PhD | Feb 5, 2019 | 0 Comments

Potential Cognitive Benefits of Intensive Blood Pressure Lowering By Heather Nelson Cortes, PhD and Kevin C Maki, PhD Currently there are no well-established clinical interventions for the prevention of mild cognitive impairment (MCI) or dementia.  Alzheimer’s disease and dementia are expected to affect 115 million people worldwide by the year 20501.  More than 75% of

Read More

Comparing the Effectiveness of Second-line Antidiabetic Medications on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus

By Mary R Dicklin PhD Kevin Maki PhD | Dec 31, 2018 | 0 Comments

Comparing the Effectiveness of Second-line Antidiabetic Medications on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus By Mary R Dicklin, PhD and Kevin C Maki, PhD, CLS, FNLA   Cardiovascular disease is the leading cause of morbidity and mortality among patients with type 2 diabetes (T2D).1  Metformin is widely recommended as first-line therapy, but

Read More

2018 American College of Cardiology/American Heart Association Cholesterol Clinical Practice Guidelines

By Heather Nelson Cortes PhD and Kevin C Maki PhD | Dec 3, 2018 | 0 Comments

2018 American College of Cardiology/American Heart Association Cholesterol Clinical Practice Guidelines 2018 American College of Cardiology/American Heart Association Cholesterol Clinical Practice Guidelines  By Heather Nelson Cortes, PhD, Mary R Dicklin, PhD and Kevin C Maki, PhD   The American College of Cardiology (ACC) and the American Heart Association (AHA) recently released their 2018 Guideline on

Read More

Summaries of Late-breaking Science Presentations at the 2018 American Heart Association meeting in Chicago, IL

By Heather Nelson Cortes PhD and Kevin C Maki PhD | Nov 30, 2018 | 0 Comments

Summaries of Late-breaking Science Presentations at the 2018 American Heart Association meeting in Chicago, IL Summaries of Late-breaking Science Presentations at the 2018 American Heart Association meeting in Chicago, IL  By Heather Nelson Cortes, PhD and Kevin C Maki, PhD  Dapagliflozin and Cardiovascular Events in the DECLARE-TIMI 58 Trial The Dapagliflozin Effect on Cardiovascular Events—Thrombolysis

Read More

More Recent Headlines from the Late-breaking Clinical Trial Presentations at the American Heart Association Scientific Sessions 2

By Kevin C Maki PhD and Mary R Dicklin PhD | Nov 29, 2018 | 0 Comments

More Recent Headlines from the Late-breaking Clinical Trial Presentations at the American Heart Association Scientific Sessions – Less Pessimism Called for When Interpreting the Results from VITAL Regarding Cardiovascular Benefits with Omega-3   By Kevin C Maki, PhD and Mary R Dicklin, PhD  The primary results from the Vitamin D and Omega-3 Trial (VITAL) were

Read More

Recent Headlines from the Late-breaking Clinical Trial Presentations at the American Heart Association Scientific Sessions

By Kevin C Maki PhD and Mary R Dicklin PhD | Nov 27, 2018 | 1 Comment

Recent Headlines from the Late-breaking Clinical Trial Presentations at the American Heart Association Scientific Sessions – REDUCE-IT – a Landmark Cardiovascular Outcomes Study of an Omega-3 Fatty Acid   By Kevin C Maki, PhD and Mary R Dicklin, PhD  The primary results from the Reduction of Cardiovascular Events with Eicosapentaenoic Acid (EPA) – Intervention Trial

Read More

Mechanisms Responsible for the Benefit on Cardiovascular Risk in the REDUCE-IT Trial

By Kevin Maki PhD | Oct 12, 2018 | 0 Comments

Mechanisms Responsible for the Benefit on Cardiovascular Risk in the REDUCE-IT Trial By Kevin C Maki, PhD   Recently, we learned of the impressive topline results from the Reduction of Cardiovascular Events with Eicosapentaenoic Acid (EPA) – Intervention Trial (REDUCE-IT), which showed that Vascepa® (icosapent ethyl or EPA ethyl esters) lowered major adverse cardiovascular events

Read More

Meta-regression Characterizes the Relationships Between Changes in Dietary Cholesterol Intake and Plasma Low-density and High-density Lipoprotein Cholesterol Changes

By Kevin Maki PhD | Oct 11, 2018 | 0 Comments

Meta-regression Characterizes the Relationships Between Changes in Dietary Cholesterol Intake and Plasma Low-density and High-density Lipoprotein Cholesterol Changes By Kevin C Maki, PhD and Orsolya M Palacios, PhD   Our group recently collaborated with scientists from the University of Cincinnati to conduct meta-regression analyses that investigated the dose-response relationships between changes in dietary cholesterol intake

Read More

Topline Results from REDUCE-IT Show a Significant Reduction in Cardiovascular Outcomes with Omega-3 Fatty Acid

By Kevin C Maki PhD and Mary R Dicklin PhD | Oct 11, 2018 | 0 Comments

Topline Results from REDUCE-IT Show a Significant Reduction in Cardiovascular Outcomes with Omega-3 Fatty Acid By Kevin C Maki, PhD and Mary R Dicklin, PhD   Exciting topline results from the Reduction of Cardiovascular Events with Eicosapentaenoic Acid (EPA) – Intervention Trial (REDUCE-IT) were recently announced by Amarin, the maker of Vascepa®.1 The full results

Read More

Results from A Study of Cardiovascular Events in Diabetes (ASCEND): Taking a Closer Look at the Potential Benefit of Omega-3 Fatty Acids for Preventing Cardiac Death

By Kevin C Maki PhD and Mary R Dicklin PhD | Sep 13, 2018 | 0 Comments

Results from A Study of Cardiovascular Events in Diabetes (ASCEND): Taking a Closer Look at the Potential Benefit of Omega-3 Fatty Acids for Preventing Cardiac Death By Kevin C Maki, PhD; Mary R Dicklin, PhD   Results from A Study of Cardiovascular Events in Diabetes (ASCEND) were recently presented at the European Society of Cardiology

Read More